GlassScriptPhysician profile
Ashraf M Mohammed
NPI 1396767091
$1,816.67
in general payments reported to CMS, 2019-2025
17 companies · $76.50 in 2025
The $76.50 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $147 · 2021: $282 · 2022: $340 · 2023: $152 · 2024: $443 · 2025: $76.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $659 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $658.50 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $266.63 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $235.87 | 2019-2024 | Ultomiris |
| Glaxosmithkline, LLC. | $226.21 | 2020-2023 | Benlysta |
| Fresenius USA Marketing, INC. | $184.53 | 2019-2024 | Velphoro, Korsuva |
| Mallinckrodt Hospital Products INC. | $164.78 | 2020-2024 | Terlivaz |
| Amgen INC. | $120.79 | 2019-2024 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $119.01 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $116.66 | 2022-2023 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $73.80 | 2019-2020 | |
| Horizon Therapeutics Plc | $66.72 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.07 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $48.78 | 2019 | |
| Vifor Pharma, INC. | $39.23 | 2019 | |
| Travere Therapeutics, INC. | $34.02 | 2024 | |
| Akebia Therapeutics INC | $24.47 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $16.62 | 2024 | Jardiance |
| Cormedix INC. | $14.48 | 2024 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Mohammed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.